It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Advance your transporter drug discovery with Sygnature Discovery’s Transporter Discovery Platform, featuring custom cell-based tools and advanced technologies, to deliver robust data and accelerate your research.
Sygnature Discovery’s advanced SLC Transporter assays are designed to identify small molecule modulators and accelerate transporter-targeted drug discovery.
Human Solute Carrier (SLC) transporters are essential proteins that regulate molecule and ion movement across cell membranes, supporting processes such as nutrient uptake, waste removal, and cell signalling. Their role in cellular balance makes them promising therapeutic targets, with dysfunction linked to cancers, CNS disorders, and metabolic diseases.
custom assay development
Sygnature Discovery’s target development group designs specialized assays precisely tailored to fit your unique discovery research needs.
Our extensive assay capabilities enable fluorescence-based screening assays and state-of-the-art transporter electrophysiology to support identification of novel starting points for lead optimization.
Working closely with your team, we customize assays to address project-specific challenges, delivering robust, reliable data that supports and enhances each stage of your drug discovery journey.
Access to the transporter assays you need
Amino Acid Transporters
SLC1A1
EAAT3
SLC1A2
EAAT2
SLC1A3
EAAT1
Class II Transporters
SLC2A9
GLUT9
Sodium-Dependent Glucose Transporters
SLC5A1
SGLT1
SLC5A2
SGLT2
SLC5A4
SGLT3
SLC5A9
SGLT4
SLC5A10
SGLT5
SLC5A7
CHT
SLC5A11
SGLT6
Sodium Calcium Exchangers
SLC8A1
NCX1
Peptide Transporters
SLC15A1
PepT1
SLC15A2
PepT2
SLC15A3
PHT2
Nucleoside Transporters
SLC28A1
CNT1
Metal Ion Transporters
SLC39A2
ZIP2
Heteromeric Amino Acid Transporters
SLC7A2b
CAT2b
SLC7A3
CAT3
SLC7A5
LAT1
Neurotransmitter Transporters
SLC6A2b
NET1
SLC6A3
DAT1
SLC6A4
CERT
SLC6A1
GAT1
SLC6A11
GAT3
SLC6A9
GLYT1
SLC6A5
GLYT2
SLC6A19
BOAT1
Cation-Coupled Chloride Transporters
SLC12A1b
NKCC2b
SLC12A2
NKCC1
SLC12A4
KCC1
SLC12A5a
KCC2a
SLC12A5b
KCC2b
Organic Cation and Anion Transporters
SLC22A2
OCT2
Proton-Coupled Amino Acid Transporters
SLC36A1
PAT1
SLC36A2
PAT2
Leading Technologies for Rapid, Reliable Results
Radiolabel Uptake Assays
Radiolabel uptake assays offer a highly sensitive and reliable way to measure SLC transporter activity providing direct insight into transporter function.
Fluorescence-Based Screening
Fluorescence-based screening assays offer rapid 384 and 1536-well formats to help identify novel modulators of SLC transporters.
Electrophysiology Studies
Our SSME technology provides precise, reliable electrophysiological assessment of transporter activity. SSME systems enable flexible, high-sensitivity screening and characterization of compounds targeting electrogenic transporters.
Two-Electrode voltage-Clamp
Two-Electrode Voltage-Clamp (TEVC) enables sensitive, reproducible measurements of electrogenic transporter activity in Xenous laevis oocytes. TEVC provides an efficient and reliable way to assess responses to compounds and measure transporter function, supporting target validation, hit identification and lead profiling.
Understanding how compounds modulate neurotransmitter transport is critical in the development of psychiatric medications. This…
Posters
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
